Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 12/20 | 0.48 |
| ▸ | HRH1 | P35367 | 12/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094334 | 0.88 | HRH2 (0.61) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL6095474 | 0.85 | HRH1 (0.50) | HRH2HRH1HRH3KCNA5ALDH1A1 | |
| SCHEMBL6096348 | 0.85 | KCNH2 (0.48) | ALDH1A1MAPT | |
| SCHEMBL5965780 | 0.84 | HRH2 (0.45) | HRH2HRH1HRH3KCNA5ALDH1A1 | |
| SCHEMBL6095760 | 0.82 | HRH1 (0.39) | HRH2HRH1HRH3ADAM17 | |
| SCHEMBL6093983 | 0.82 | ADAM17 (0.40) | HRH2HRH1HRH3ADAM17 | |
| SCHEMBL6095505 | 0.82 | GPR119 (0.51) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL6096247 | 0.82 | HRH1 (0.57) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL6094981 | 0.82 | HRH2 (0.49) | HRH2HRH1HRH3KCNA5 | |
| SCHEMBL7252026 | 0.81 | HRH2 (0.41) | HRH2HRH1HRH3KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | HRH2 2122/4885HRH1 2707/4885HRH3 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.